Validity and reliability of linear encoder muscle power testing in persons with Parkinson's disease.
This note indexes a cited or audit-added source. It may be an original study, review, guideline, form or methods reference. Treat the specific design and the evidence below as authoritative; a source note is not automatically a primary study.
DOI: 10.1177/02692155231224987
Bibliographic record from the original reports
Access labels embedded in these original reference strings are historical. Current access and exact checked components are stated separately below.
Bonde-Jensen F, Dalgas U, Hvid LG, Langeskov-Christensen M. Validity and reliability of linear encoder muscle power testing in persons with Parkinson's disease. Clin Rehabil. 2024;38(5):678–687. DOI 10.1177/02692155231224987
Conditions: COND-PD Parkinson’s disease
Scoped audit evidence
These are source- and component-level audit summaries as of 3 October 2026. Access and comparison scope can differ by report; none certifies every result or the underlying raw data.
Parkinson’s disease — strength
- access status: full_main_text_available
STR-04-06
STR-04-01
STR-04-02
STR-04-03
STR-04-04
STR-04-05
Limitations: Only current scoped checks; archived captures not authenticated against live originals.
Parkinson’s disease strength
- current access: full_main_text_available
- primary version: Archived licensed publisher HTML/text capture; figure captions only; separate supplement unavailable
Parkinson’s disease strength component — Complete core encoder acquisition and execution as reported
Methods Outcomes gives CHRONOJUMP Bosco v 1.8.1, 1000 Hz, concentric rise as fast/powerful as possible, fully erect without lifting feet, best peak-power of two attempts with 30–60 s rest. Further chair/attachment/position/processing details are delegated to supplementary material; the main text does not provide them. The separate supplement remains unavailable in this audit.
Source locator: https://doi.org/10.1177/02692155231224987; Library original archived audit evidence Outcomes and Supplementary Material
Limitations: The unavailable supplement prevents certification of a complete transferable protocol; the report does not invent those details. AI-assisted comparison with archived licensed capture; transcription accuracy was not independently verified against the live publisher original.
Parkinson’s disease strength component — Construct cohort, exact power comparisons and validation limits
Methods and Tables 1–2:70 PD enrolled, one technical loss, 69 analyzed versus 35 controls; ON testing;14.1 versus 15.2 W/kg, difference−1.1 [−2.8, .5]. Moderate MDS-UPDRSIII≥33 subgroup n 10 has lower power. Results reports functional r² .44–.51, associations retained after age/sex adjustment. Limitations explicitly says criterion/content validity still need assessment; there is no concurrent reference-device agreement experiment.
Source locator: https://doi.org/10.1177/02692155231224987; Library original archived audit evidence Methods, Results, Tables 1–2 and Limitations
Limitations: AI-assisted comparison with archived licensed capture; transcription accuracy was not independently verified against the live publisher original.
Parkinson’s disease strength component — Repeatability design, exclusions, medication comparison and generalizability
Study 2 n 20, paired randomized state order, four visits 4–16 days apart, two ON/two approximately 12-hour OFF. One ON technical loss and one withdrawal after OFF pain/fatigue yield 19 paired observations/state. Table 1 mean HY 2, duration 4.3 years;eligibility HY≤3. Results ON–OFF mean difference .4 W/kg [−.6, 1.3]. The main text supplies no exact post-dose ON interval or dyskinesia subgroup. Feet-grounded ceiling concern is explicitly acknowledged.
Source locator: https://doi.org/10.1177/02692155231224987; Library original archived audit evidence Study design, Tables 1/3, Results and Limitations
Limitations: AI-assisted comparison with archived licensed capture; transcription accuracy was not independently verified against the live publisher original.
Parkinson’s disease strength component — All four report Table 6 rows and normalized agreement-limit discrepancy
Table 3 exactly matches report means/SDs, ICC 2, 1 absolute-agreement CIs, SDC 1.0/1.3 W/kg and 66/90 W, SEM%2.1/2.9 and 1.7/2.5, and differences−.3/+ .2 W/kg, −23/+19 W. Figure 3 captions and Results give ON LOA−3.3 to 2.7 and OFF−3.3 to 3.6 W/kg, n 19 each. Discussion explicitly proposes 5.7%/7.9% and acknowledges larger Bland–Altman dispersion. Formula details are delegated to ref 23. The report correctly quarantines this source conflict; half-widths 3.0/3.45 are audit arithmetic, not validated replacements.
Source locator: https://doi.org/10.1177/02692155231224987; Library original archived audit evidence Statistical analysis, Table 3, Figure 3 captions, Results/Discussion
Limitations: Figure images and the earlier formula paper were not reanalyzed; all report numeric limits are independently present in primary text/captions. AI-assisted comparison with archived licensed capture; transcription accuracy was not independently verified against the live publisher original.
Reports citing this source
- Strength muscle power and rapid force production assessment in Parkinson’s disease · reference 4 · original reference
Update record
- 2026-10-03: Created from the supplied reports and final scoped audit. New evidence should be appended with source version, access date, exact locator and affected report links.
Updating the wiki · Evidence and status guide